Figure 6
From: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Structural basis for the lack of the binding of anti-PD-L1 antibodies to PD-L2. (a) The partially transparent surface model of atezolizumab (green) when PD-L1 of PD-L1/atezolizumab is overlaid onto PD-L2 (red, PDB code 3bov). (b) The surface model of durvalumab (blue) when PD-L1 of PD-L1/durvalumab is overlaid onto PD-L2. (c) The surface model of BMS-963559 (gray) when PD-L1 of PD-L1/BMS-963559 is overlaid onto PD-L2. (d) The surface model of avelumab (yellow) when PD-L1 of PD-L1/avelumab is overlaid onto PD-L2. In (a–d) the residues of the antibodies, which collide with W110 of PD-L2, are shown in sticks and labeled. (e) Structure-based sequence alignment of PD-L1 and PL-L2. The strands in PD-L1 are denoted with arrows above the sequence. W110 of PD-L2 is indicated with an asterisk. The identical and homologous residues are colored red and green, respectively.
